Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Sell
27
BPMC Quote, Financials, Valuation and Earnings
Last price:
$82.04
Seasonality move
:
9.28%
Day range:
$73.04 - $83.54
52-week range:
$73.04 - $121.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.23x
P/B ratio:
17.56x
Volume:
1.9M
Avg. volume:
1.1M
1-year change:
-11.01%
Market cap:
$5.2B
Revenue:
$508.8M
EPS (TTM):
-$1.08
Analysts' Opinion
-
Consensus RatingBlueprint Medicines has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 5 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $126.43, Blueprint Medicines has an estimated upside of 54.09% from its current price of $82.05.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $83.00 representing -1.16% downside risk from its current price of $82.05.
Fair Value
-
According to the consensus of 17 analysts, Blueprint Medicines has 54.09% upside to fair value with a price target of $126.43 per share.
BPMC vs. S&P 500
-
Over the past 5 trading days, Blueprint Medicines has underperformed the S&P 500 by -15.24% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Blueprint Medicines does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Blueprint Medicines has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Blueprint Medicines reported revenues of $146.4M.
Earnings Growth
-
Blueprint Medicines has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Blueprint Medicines reported earnings per share of -$0.79.
Enterprise value:
5B
EV / Invested capital:
--
Price / LTM sales:
10.23x
EV / EBIT:
1,703.45x
EV / Revenue:
9.86x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-25.43x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
260.72x
Gross Profit (TTM):
$488.7M
Return On Assets:
-5.92%
Net Income Margin (TTM):
-13.19%
Return On Equity:
-24.43%
Return On Invested Capital:
-11.14%
Operating Margin:
-28.15%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $204M | $249.4M | $508.8M | $72M | $146.4M | |
| Gross Profit | $186.2M | $240.8M | $488.7M | $71.7M | $138.9M | |
| Operating Income | -$528.6M | -$482M | -$212M | -$105.2M | -$41.2M | |
| EBITDA | -$513.6M | -$442.7M | $19.2M | -$94.3M | -$27.1M | |
| Diluted EPS | -$9.35 | -$8.36 | -$1.08 | -$1.82 | -$0.79 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $927.8M | $554M | $1B | $808.4M | $742.7M | |
| Total Assets | $1.7B | $1.3B | $1.3B | $1B | $1.2B | |
| Current Liabilities | $130.8M | $149.8M | $183.2M | $214.9M | $260.8M | |
| Total Liabilities | $248.3M | $281.5M | $835.2M | $918.6M | $881.1M | |
| Total Equity | $1.5B | $970.7M | $514.7M | $130.6M | $298.7M | |
| Total Debt | -- | -- | $139.1M | $238.8M | $387M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$502.3M | -$436.8M | -$192.6M | -$78.9M | -$29.4M | |
| Cash From Investing | -$149.5M | $274M | -$47.5M | $78.8M | $33.7M | |
| Cash From Financing | $561.8M | $119.2M | $273.1M | $15.5M | $9.8M | |
| Free Cash Flow | -$511.2M | -$452.9M | -$197.2M | -$83.6M | -$30.3M | |
BPMC
Sector
Market Cap
$5.2B
$33.7M
Price % of 52-Week High
67.31%
40%
Dividend Yield
0%
0%
Shareholder Yield
-1.42%
-0.91%
1-Year Price Total Return
-11.01%
-46.85%
Beta (5-Year)
0.746
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$84.34
200-day SMA
Sell
Level
$96.22
Bollinger Bands (100)
Sell
Level
86.86 - 103.92
Chaikin Money Flow
Buy
Level
21.8M
20-day SMA
Sell
Level
$88.05
Relative Strength Index (RSI14)
Sell
Level
39.04
ADX Line
Sell
Level
22.13
Williams %R
Neutral
Level
-60.792
50-day SMA
Sell
Level
$94.89
MACD (12, 26)
Sell
Level
-3.20
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
9.6M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.8573)
Sell
CA Score
(Annual)
Level (-1.6858)
Sell
Beneish M-Score
(Annual)
Level (-1.1146)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (5.1911)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Stock Forecast FAQ
In the current month, BPMC has received 11 Buy ratings 5 Hold ratings, and 1 Sell ratings. The BPMC average analyst price target in the past 3 months is $126.43.
-
Where Will Blueprint Medicines Stock Be In 1 Year?
According to analysts, the consensus estimate is that Blueprint Medicines share price will rise to $126.43 per share over the next 12 months.
-
What Do Analysts Say About Blueprint Medicines?
Analysts are divided on their view about Blueprint Medicines share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Blueprint Medicines is a Sell and believe this share price will drop from its current level to $83.00.
-
What Is Blueprint Medicines's Price Target?
The price target for Blueprint Medicines over the next 1-year time period is forecast to be $126.43 according to 17 Wall Street analysts, 11 of them rate the stock a Buy, 1 rates the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is BPMC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Blueprint Medicines is a Buy. 11 of 17 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BPMC?
You can purchase shares of Blueprint Medicines via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Blueprint Medicines shares.
-
What Is The Blueprint Medicines Share Price Today?
Blueprint Medicines was last trading at $82.04 per share. This represents the most recent stock quote for Blueprint Medicines. Yesterday, Blueprint Medicines closed at $82.05 per share.
-
How To Buy Blueprint Medicines Stock Online?
In order to purchase Blueprint Medicines stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Stock Ideas
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
33
BULZ alert for Apr 10
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 15.97% over the past day.
Sell
31
TECS alert for Apr 10
Direxion Daily Technology Bear 3x Shares [TECS] is up 14.16% over the past day.
Sell
48
FNGA alert for Apr 10
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 13.77% over the past day.
